SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a study revealing that more patients completed hereditary cancer testing when they used an online ...

Myriad Genetics faces a tough year ahead with new policy changes. Learn why MYGN stock has cratered and if it's poised for ...

Myriad develops and offers genetic tests that help assess the risk of developing ... improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

A systematic review highlights the potential of genomic tests in prostate cancer treatment decisions but calls for more data ...

Myriad Genetics is a molecular diagnostics company that provides testing services designed to ... showcases strong profitability and effective cost control. Return on Equity (ROE): Myriad ...

SALT LAKE CITY, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision ... and loss contingencies, costs related to acquisitions ...

Myriad Genetics, Inc. announced its preliminary ... (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter ...

SALT LAKE CITY, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced select unaudited preliminary results for the ...

Myriad develops and offers genetic tests that help assess the risk of developing disease ... genetic insights can significantly improve patient care and lower healthcare costs. For more information, ...